Figure 8. Proposed Algorithm for the Evaluation of Cardiac Involvement in EGPA.^In our experience, 3-6 months is an appropriate time interval to detect improvements in inflammation on CMR. Frequency of further surveillance imaging should be tailored to the individual and requires the input of the multidisciplinary team. Cardiac-gated FDG-PET may be considered as an alternative/adjunctive diagnostic imaging technique in those who have contraindication/intolerance to CMR, or in those in whom uncertainty remains.*Consider EMB for histopathological diagnosis dependent on patient preference and local expertise.BNP, B-type natriuretic peptide; CMR, cardiac magnetic resonance; ECG, electrocardiogram; EGPA, eosinophilic granulomatosis with polyangiitis; EMB, endomyocardial biopsy; NT-proBNP, N-terminal B-type natriuretic peptide; TTE, transthoracic echocardiography.
